Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study

Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study

Item
http://www.wikidata.org/entity/Q33962155
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaRedox-directed cancer therapeutics: molecular mechanisms and opportunitiesEnhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism.Arsenic trioxide - An old drug rediscovered.Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaTargeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface.Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic.Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.Effects of arsenic sulfide (As2S2) on B and T lymphoma cell lines and possible underlying mechanisms.Cucurbitacin B synergistically enhances the apoptosis-inducing effect of arsenic trioxide by inhibiting STAT3 phosphorylation in lymphoma Ramos cells.Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA).
P2860

Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study

Item
http://www.wikidata.org/entity/Q33962155
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase II study of arsenic trio ...... sconsin Oncology Network study
@ast
Phase II study of arsenic trio ...... sconsin Oncology Network study
@en
type
label
Phase II study of arsenic trio ...... sconsin Oncology Network study
@ast
Phase II study of arsenic trio ...... sconsin Oncology Network study
@en
prefLabel
Phase II study of arsenic trio ...... sconsin Oncology Network study
@ast
Phase II study of arsenic trio ...... sconsin Oncology Network study
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Phase II study of arsenic trio ...... sconsin Oncology Network study
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932